ZLAB (Zai Lab) Tariff Resilience Score: 7/10 (As of Jun. 26, 2026)


ZLAB Zai Lab Ltd ZLAB
64 GF Score
Price $18.52
GF Value $30.30
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Zai Lab Tariff Resilience Score?

Zai Lab ZLAB +0.76% 64 Tariff Resilience Score is 7 as of Jun. 26, 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,378 Biotechnology companies, Zai Lab ranks better than 90.42% on this metric.

Zai Lab has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Zai Lab has Zai Lab Ltd has a strong domestic market presence and diversified global partnerships, reducing tariff exposure. The pharmaceutical industry benefits from some tariff exemptions, and the company has shown resilience to past tariff changes through strategic alliances.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Zai Lab might have Highly Resilient.

Zai Lab  (NAS:ZLAB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Zai Lab Tariff Resilience Score Related Terms

ZLAB vs TYRA, TRVI, OCUL: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Zai Lab's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zai Lab Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Zai Lab's Tariff Resilience Score falls into.


ZLAB
64GF Score
Zai Lab Ltd ZLAB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Zai Lab (ZLAB) has a Tariff Resilience Score of 7 as of Jun. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Zai Lab ranks #132 out of 1378 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Zai Lab's Tariff Resilience Score too high?
Zai Lab's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Zai Lab's value of 7 is 75% above this industry median. Based on the distribution chart, Zai Lab ranks #132 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Tariff Resilience Score compare to TYRA and TRVI?
According to the Biotechnology industry distribution chart, Zai Lab ranks #132 out of 1378 companies for Tariff Resilience Score. This places Zai Lab in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Zai Lab's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zai Lab's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.52 — trading 38.9% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Zai Lab (ZLAB), the current Tariff Resilience Score is 7 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (ZLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of $18.52 is trading 38.9% below its estimated GF Value™ of $30.30. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for ZLAB:

  • Tariff Resilience Score: 7
  • GF Value™: $30.30 vs. price of $18.52 (38.9% below fair value)
  • GF Score™: 64/100 with 8 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1378)

No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Other Exchanges 09688:Hong Kong1ZLB:Germany
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for ZLAB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.52
Price
$30.30
GF Value